Cosmo Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Cosmo Pharmaceuticals has a total shareholder equity of €505.4M and total debt of €559.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are €638.3M and €132.9M respectively. Cosmo Pharmaceuticals's EBIT is €86.0M making its interest coverage ratio 154.4. It has cash and short-term investments of €133.4M.
Key information
0.1%
Debt to equity ratio
€559.00k
Debt
| Interest coverage ratio | 154.4x |
| Cash | €133.41m |
| Equity | €505.39m |
| Total liabilities | €132.87m |
| Total assets | €638.25m |
Recent financial health updates
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well
Aug 02Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly
Apr 03Recent updates
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable
Nov 22Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues
May 02Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well
Aug 02Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)
May 20Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly
Apr 03When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?
Mar 07Financial Position Analysis
Short Term Liabilities: COPN's short term assets (€183.6M) exceed its short term liabilities (€37.9M).
Long Term Liabilities: COPN's short term assets (€183.6M) exceed its long term liabilities (€95.0M).
Debt to Equity History and Analysis
Debt Level: COPN has more cash than its total debt.
Reducing Debt: COPN's debt to equity ratio has reduced from 38.9% to 0.1% over the past 5 years.
Debt Coverage: COPN's debt is well covered by operating cash flow (20988.6%).
Interest Coverage: COPN's interest payments on its debt are well covered by EBIT (154.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 04:45 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cosmo Pharmaceuticals N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Laura Pfeifer-Rossi | Bank am Bellevue |
| Silvia Schanz | Bank Vontobel AG |
| Laura Hindley | Berenberg |